首页> 美国卫生研究院文献>International Journal of Surgical Oncology >Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer
【2h】

Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer

机译:新辅助腹膜内/全身化学疗法(双向化学疗法)治疗胃癌腹膜转移患者的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Novel multidisciplinary treatment combined with neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS) and peritonectomy was developed. Ninety-six patients were enrolled. Peritoneal wash cytology was performed before and after NIPS through a port system. Patients were treated with 60 mg/m2 of oral S-1 for 21 days, followed by a 1-week rest. On days 1, 8, and 15, 30 mg/m2 of Taxotere and 30 mg/m2 of cisplatin with 500 mL of saline were introduced through the port. NIPS is done 2 cycles before surgery. Three weeks after NIPS, 82 patients were eligible to intend cytoreductive surgery (CRS) by gastrectomy + D2 dissection + periotnectomy to achieve complete cytoreduction. Sixty-eight patients showed positice cytology before NIPS, and the positive cytology results became negative in 47 (69%) patients after NIPS. Complete pathologic response on PC after NIPS was experienced in 30 (36.8%) patients. Stage migration was experienced in 12 patients (14.6%). Complete cytoreduction was achieved in 58 patients (70.7%). By the multivariate analysis, complete cytoreduction and pathologic response became a significantly good survival. However the high morbidity and mortality, stringent patient selection is important. The best indications of the therapy are patients with good pathologic response and PCI ≤ 6, which are supposed to be removed completely by peritonectomy.
机译:开发了新的多学科治疗与新辅助腹膜内全身化疗方案(NIPS)和腹膜切除术相结合。纳入96例患者。通过端口系统在NIPS之前和之后进行腹膜冲洗细胞学检查。患者接受60μmg/ m 2 口服S-1治疗21天,然后休息1周。在第1、8和15天,通过港口引入30mg / m 2 的泰索帝和30μmg/ m 2 的顺铂和500ul的盐水。 NIPS在手术前2个周期完成。 NIPS后三周,有82例患者符合资格通过胃切除术+ D2解剖+腹膜切除术进行细胞减灭术(CRS)以实现完全的细胞减少。 NIPS之前有68位患者表现出阳性细胞学,NIPS后47位(69%)患者的细胞学阳性结果变为阴性。 30例(36.8%)患者经历了NIPS后,PC发生了完全的病理反应。 12名患者(14.6%)经历了阶段性迁移。 58名患者(70.7%)实现了完全的细胞减少。通过多变量分析,完全的细胞减少和病理反应成为显着良好的生存期。但是高发病率和高死亡率,严格的患者选择很重要。该疗法的最佳适应症是病理反应良好且PCI≤6的患者,这些患者应通过腹膜切除术彻底清除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号